On September 11, 2020 Oragenics, Inc. (NYSE American: OGEN), a biopharmaceutical company dedicated to the development and commercialization of a vaccine candidate to combat the novel coronavirus pandemic (commonly referred to as COVID-19) reported that Alan Joslyn, Ph.D., President and Chief Executive Officer, is scheduled to present at the H.C. Wainwright 22nd Annual Global Investment Conference (the "Conference") (Press release, Oragenics, SEP 11, 2020, View Source [SID1234565026]). The Conference is to be held virtually on September 14–16, 2020, and Dr. Joslyn is scheduled to present on Wednesday, September 16, 2020 at 11:00 AM ET.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A live webcast of Dr. Joslyn’s presentation will be available through H.C. Wainwright’s virtual conference portal, located here, and the presentation will be archived on the Oragenics website at View Source

In addition, Dr. Joslyn will be available for virtual one-on-one meetings from September 14–16, 2020. To schedule a meeting with Dr. Joslyn, please contact the Conference coordinator at [email protected].